hypertension cost effectiveness mark caulfield for the british hypertension society the william...
TRANSCRIPT
Hypertension Cost effectiveness
Mark Caulfield
For the British Hypertension Society
The William Harvey Research Institute and Barts and The London NIHR Biomedical Research Unit
Queen Mary University of London
Launch: Wednesday 24th August 2011
NICE clinical guideline 127
The guideline
2004: National Institute for Health and Clinical Excellence (NICE) hypertension guideline
2006: Drug model developed as part of pharmacological update to guideline
2011: Model updated during second guideline update
National Collaborating Centre for Chronic Conditions
Model overviewPopulation
•Patients with essential hypertension seen in primary care
•Base case patient: 65-year-old men and women with 2% CVD risk, 1% HF risk and 1.1% diabetes risk
Comparators
•no intervention (NI)
•thiazide-type diuretics (TD)
•calcium-channel blockers (CCB)
•beta-blockers (BB)
•ACE inhibitors/angiotensin-II receptor antagonists (ACE/ARB)
Perspective and time horizon
•UK NHS perspective, lifetime horizon
Model overview: model structureMarkov model
Health states chosen to represent disease (simplification/data dependant)
•Transitions between health states affected by the effectiveness of treatments over time (Cycles)
Model inputs: drug effectiveness
•Systematic clinical review and meta analysis
•Head to head studies off different drug classes reporting various clinical outcomes
OutcomeThiazide-type diuretics (D)
Calcium-channel blockers (C)
Beta-blockers (B)
ACEi/ARB (A)
UA 0.893 0.881 0.984 1.01MI 0.78 0.796 0.855 0.85Diabetes 0.985 0.808 1.137 0.77Stroke 0.69 0.656 0.851 0.69Heart failure 0.53 0.731 0.761 0.65
Death 0.91 0.883 0.939 0.9
Studies included in systematic review•ALLHAT 2002
•ANBP2 2003
•ASCOT 2005
•CORD 2009
•ELSA 2002
•HAPPHY 1987
•INSIGHT 2000
•INVEST 2003
•JMIC-B 2004
•LIFE 2002
•MIDAS 1998
•MRC 1985
•MRC-0 1992
•NICS-EH 1999
•ONTARGET 2008
•PHYLLIS 2004
•SHEP-P 1985
•SHEP 1991
•STOP-H2 1999
•SYST-EUR 2000
•Tedesco 2007
•VALUE 2004
•VHAS 1998
Model inputs: drug costs
UK generic list prices (BNF)Drug used in model 2011 Yearly drug
cost (EUR)2006 Yearly drug cost (EUR)
ACEiRamipril (10mg)
£21 (€26) £30 (€49)
ARBLosartan (100mg)
£26 (€32) £217 (€287)
BBAtenolol (100mg)
£13 (€16) £13 (€17)
CCBAmlodipine (10mg)
£19 (€24) £70 (€92)
DDBendroflumethiazide (2.5mg)
£12 (€15) £17 (€22)
Interpreting cost effectiveness results•Clinical and cost effectiveness
•Cost effectiveness = Costs and health outcomes and getting the most health gain from the resources available
•Health is measured in QALYs
•Life years x QoL (Utility) = QALY
=
Cost per QALY gained
Difference in costs
Difference in QALYs
=
Incremental cost-effectiveness ratio (ICER)
Health economics of HTN therapy 2006
Health economics of HTN therapy 2011
Uncertainty - sensitivity analysis
•Varying individual parameters to test sensitivity of model results
•Risk of CVD events (HF, MI, UA etc...)•Effectiveness of drugs•Cost of drugs and events•Side effects of drugs
•Model remained fairly robust to changes
•In a few extreme scenario analyses, other drugs became cost effective (mainly diuretics)
Interpretation•Treatment of hypertension is highly cost effective
•Based on UK, generic drug prices
•CCBs are the most cost effective option with an ICER below £2,000
•The results are more robust than in the 2006 model
•As commonly used anti-hypertensives become generic it is now cheaper to treat hypertension than to do nothing
AcknowledgementsKate Lovibond
Ralph Hughes
Prof Bryan Williams
Leo Nherera
Joanne Lord
2006 hypertension (update) GDG members
2011 hypertension (update) GDGmembers
British Hypertension Society
National Institute for Health and Clinical Excellence